Pyrazoloacridine for the treatment of hormone-refractory prostate cancer

Cancer Investigation

Volumn 16, Issue 7, 1998, Pages 456-461

  Small, Eric J ^a,b   Fippin, Linda J ^a   Whisenant, Sarah P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ACRIDINE DERIVATIVE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG EFFICACY; FATIGUE; HUMAN; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALE GENITAL TRACT CANCER; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOPHLEBITIS; TREATMENT OUTCOME; VOMITING;

EID: 0031662119     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809011699     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA: A Cancer Journal for Clinicians 65:5-27, 1996.
2. Gittes R: Carcinoma of the prostate. N Engl J Med 324:236-245, 1991.
3. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993.
4. Small EJ, Srinivas S: The antiandrogen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Cancer 15:1428-1434, 1995.
5. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma. J Clin Oncol 3:827-841, 1985.
6. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 3:1013-1021, 1985.
7. Hudes GR, Greenberg R, Krigel RL: Phase II study of estramustine and vinblastine, 2 microtubule inhibitors in hormone refractory prostate cancer. J Clin Oncol 10(11):1754-1761, 1992.
8. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol 147:931-934, 1992.
9. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994.
10. Hudes GR, Nathan FE, Khater C, et al: Paclitaxel plus estramustine in metastatic hormone refractory prostate cancer. Semin Oncol 22:41-45, 1995.
11. Sella A, Kilbourn R, Amato R, et al: Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12:683-688, 1994.
12. Small EJ, Srinivas S, Egan B, et al: Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony stimulating factor for the treatment of hormone resistant prostate cancer. J Clin Oncol 14:1617-1625, 1996.
13. Tannock I, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer. A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996.
14. Kantoff PW, Conoway M, Winer E, et al: Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: preliminary results from a prospective randomized Cancer and Leukemia Group B Study (9182). Proc Am Soc Clin Oncol 15:25, 1996.
15. Kobayashi K, Vokes EE, Vogelzang NJ, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196-2207, 1995.
16. Reyno LM, Egorin MJ, Eisenberger MA, et al: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-2195, 1995.
17. Kelly WK, Curley T, Liebertz C, et al: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13:2208-2213, 1995.
18. Jackson RC, Leopold WR, Sebolt JS: Biochemical and experimental chemotherapy studies of the pyrazoloacridines. Proc Am Assoc Cancer Res 29:536, 1988.
19. Jackson RC, Sebolt JS, Shillis JL, et al: The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest 8:39-47, 1990.
20. Lorusso P, Wozniak AJ, Polin L, et al: Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 50:4900-4905, 1990.
21. Sebolt JS, Leopold WR, Hamelehle KL, et al: Solid tumor selectivity of the 2-aminoalkyl-t-nitro-pyrazolo [3,4,5-kl]acridines, a novel class of DNA-binding antitumor agents. Proc Am Assoc Cancer Res 27:421, 1986.
22. Sebolt JS, Scavone SV, Pinter CD, et al: Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 47:4299-4304, 1987.
23. Sebolt J, Havlick M, Hamelehle K, et al: Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24:219-224, 1989.
24. Sebolt-Leopold JS, Scavone SV: Biochemistry of the interactions between DNA and the pyrazoloacridines, a series of biologically novel anticancer agents. Proc Am Assoc Cancer Res 32:A1980, 1991.
25. Rowinsky E, Grochow L, McGuire W, et al: Phase I pharmacologic study of pyrazoloacridine (PA), a novel acridine compound, on a single 1-3 hour schedule. Proc Am Soc Clin Oncol 12:160, 1993.
26. Kelly WK, Scher HI, Mazamudar M: Prostate-specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 11(4):607-615, 1993.